We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 02, 2020

Ublituximab Use in Patients With Relapsing MS

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis
Mult. Scler. 2020 Apr 30;[EPub Ahead of Print], E Fox, AE Lovett-Racke, M Gormley, Y Liu, M Petracca, S Cocozza, R Shubin, S Wray, MS Weiss, JA Bosco, SA Power, K Mok, M Inglese

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading